Granted Patent
B2
US 12,221,422 · App. 17/699,408 · Granted Feb 11, 2025
Compounds and their use for the treatment of alpha1-antitrypsin deficiency
Inventors:
Nigel Ramsden (Babraham, GB); David John Fox (Coventry, GB); James Andrew Huntington (Babraham, GB)
Assignee:
CENTESSA PHARMACEUTICALS (UK) LIMITED
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The invention relates to oxopyrimidinyl-methyl-benzamide derivatives, for example in a pharmaceutically acceptable salt form or crystal form, pharmaceutical compositions comprising the derivatives, and their medical use, in particular for use in the treatment of α 1 -antitrypsin deficiency (A1AD or AATD).
Claims (18)
1. A method of inducing Z A1AT secretion comprising administering a compound represented by the structure of:
or a pharmaceutically acceptable salt of any one thereof.
2. The method of claim 1 , wherein the compound is represented by:
or a pharmaceutically acceptable salt thereof.
3. The method of claim 1 , wherein the compound is represented by:
or a pharmaceutically acceptable salt thereof.
4. The method of claim 1 , wherein the compound is represented by:
or a pharmaceutically acceptable salt thereof.
5. The method of claim 1 , wherein the administering to the subject in need thereof is conducted orally.
6. A method of treating αi-antitrypsin deficiency (AATD) comprising administering a compound represented by the structure of:
or a pharmaceutically acceptable salt of any one thereof.
7. The method of claim 6 , wherein the compound is represented by:
or a pharmaceutically acceptable salt thereof.
8. The method of claim 6 , wherein the compound is represented by:
or a pharmaceutically acceptable salt thereof.
9. The method of claim 6 , wherein the compound is represented by:
or a pharmaceutically acceptable salt thereof.
10. The method of claim 6 , wherein the administering to the subject in need thereof is conducted orally.
Assignments (4)
RELEASE OF SECURITY INTEREST
Recorded Jun 24, 2026
From: OXFORD FINANCE LLC
To: CENTESSA PHARMACEUTICALS (UK) LIMITED
Reel/Frame 075069/0879 →
SECURITY INTEREST
Recorded Dec 31, 2024
From: CENTESSA PHARMACEUTICALS (UK) LIMITED
To: OXFORD FINANCE LLC
Reel/Frame 069708/0039 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 20, 2023
From: Z FACTOR LIMITED
To: CENTESSA PHARMACEUTICALS (UK) LIMITED
Reel/Frame 065294/0323 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 21, 2022
From: RAMSDEN, NIGEL, DR.; FOX, DAVID JOHN, DR.; HUNTINGTON, JAMES ANDREW
To: Z FACTOR LIMITED
Reel/Frame 059452/0672 →
Priority Claims (1)
GB 1820450
· Dec 14, 2018
· national
Continuity (3)
Continuation
PCTGB2019053552
· Dec 13, 2019
References Cited (56)
US 8436013B2
· Liu et al.
· 2013
[cited by applicant]
US 20020006909A1
· Perlmutter et al.
· 2002
[cited by applicant]
US 20070167621A1
· Durley
· 2007
[cited by applicant]
US 20100070010A1
· Simpson
· 2010
[cited by applicant]
US 20100076018A1
· Liu
· 2010
[cited by examiner]
US 20150045344A1
· Von Nussbaum et al.
· 2015
[cited by applicant]
US 20160340319A1
· Gnamm et al.
· 2016
[cited by applicant]
US 20230102488A1
· Ramsden et al.
· 2023
[cited by applicant]
CN 1997649A
· 2007
[cited by applicant]
CN 101406473A
· 2009
[cited by applicant]
CN 104364237A
· 2015
[cited by applicant]
CN 115023416A
· 2022
[cited by applicant]
EP 1832586A1
· 2007
[cited by applicant]
GB 2612007A
· 2023
[cited by applicant]
JP 2007528353A
· 2007
[cited by applicant]
JP 2007530459A
· 2007
[cited by applicant]
WO WO0052034A2
· 2000
[cited by applicant]
WO WO0152830A2
· 2001
[cited by applicant]
WO WO2005092899A1
· 2005
[cited by applicant]
WO WO2008143633A2
· 2008
[cited by applicant]
WO WO2013068909A1
· 2013
[cited by applicant]
WO WO2013070657A1
· 2013
[cited by applicant]
WO WO2016031987A1
· 2016
[cited by applicant]
WO WO2019243841A1
· 2019
[cited by applicant]
WO WO2020081257A1
· 2020
[cited by applicant]
WO WO2020120992A1
· 2020
[cited by applicant]
WO WO2021116706A1
· 2021
[cited by applicant]
WO WO2021116707A1
· 2021
[cited by applicant]
WO WO2021116709A1
· 2021
[cited by applicant]
WO WO2021255429A1
· 2021
[cited by applicant]
WO WO2022263829A1
· 2022
[cited by applicant]
Berthelier et al. Discovery of an Inhibitor of Z-Alpha1 Antitrypsin Polymerization. PLoS One 10(5):e0126256 (May 11, 2015).
[cited by applicant]
Bouchecareilh et al. Histone deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA)-mediated correction of α1-antitrypsin deficiency. J Biol Chem 287(45):38265-38278 (2012).
[cited by applicant]
Burrows et al. Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency. PN…
[cited by applicant]
Carlson et al. Accumulation of PiZ alpha 1-antitrypsin causes liver damage in transgenic mice. J. Clin Invest 83:1183-90 (1989).
[cited by applicant]
Chang et al. Small-molecule peptides inhibit Z alpha1-antitrypsin polymerization. J. Cell. Mol. Med. 13(8B):2304-2316 (2009).
[cited by applicant]
Dycaico et al. Neonatal hepatitis induced by alpha 1-antitrypsin: a transgenic mouse model. Science 242:1409-12 (1988).
[cited by applicant]
Elkins et al. Variability in high-throughput ion-channel screening data and consequences for cardiac safety assessment. J Pharmacol Toxicol Methods 68:112-122 (2013).
[cited by applicant]
Elliott et al. Topography of a 2.0 A structure of alpha1-antitrypsin reveals targets for rational drug design to prevent conformational disease. Protein Science 9:1274-1281 (2000).
[cited by applicant]
Gould et al. Salt Selection for Basic Drugs. Int J. Pharm. 33:201-217 (1986).
[cited by applicant]
Huntington. How and why the Z variant of a1-antitrypson polymerises, and what can be done about it. 7th International Symposium on Serpin Biology, Structure and Function (Apr. 1, 2014).
[cited by applicant]
Huntington. How and why the Z variant of a1-antitrypson polymerises, and what can be done about it. Xiiith International Symposium on Proteinases, Inhibitors and Biological Control (Sep. 23, 2012).
[cited by applicant]
Knaupp et al. Kinetic instability of the serpin Z alpha1-antitrypsin promotes aggregation. J. Mol. Biol. 396:375-383 (2010).
[cited by applicant]
Mallya et al. Small molecules block the polymerization of Z alpha1-antitrypsin and increase the clearance of intracellular aggregates. J Med Chem 50(22):5357-5363 (2007).
[cited by applicant]
Parfrey et al. Targeting a surface cavity of alpha 1-antitrypsin to prevent conformational disease. J. Biol. Chem. 278(35):33060-33066 (2003).
[cited by applicant]
PCT/GB2019/053552 International Search Report and Written Opinion dated Mar. 2, 2020.
[cited by applicant]
Seyama et al. Siiyama (serine 53 (TCC) to phenylalanine 53 (TTC)). A new alpha 1-antitrypsin-deficient variant with mutation on a predicted conserved residue of the serpin backbone. J Biol Chem 266:12627-32 (1991).
[cited by applicant]
Weaver et al. Cytochrome P450 inhibition using recombinant proteins and mass spectrometry/multiple reaction monitoring technology in a cassette incubation. Drug Metab Dispos 31(7):955-966 (2003).
[cited by applicant]
“Aurora Building Blocks,” Chemcats, CAS Registry No. 1797054-78-4 and 1219580-65-0, 01 Page (Feb. 7, 2018).
[cited by applicant]
PCT/GB2020/053191 International Search Report and Written Opinion dated Feb. 2, 2021.
[cited by applicant]
Pubchem: “4-[(6-Oxopyrimidin-1-yl)Methyl]Benzamide,” Compound Database Accession No. CID113257346, 08 Pages (Jan. 28, 2016).
[cited by applicant]
STN Search Report, Columbus, Ohio, US Registry [Online]. STN Registry :30 Pages (2018).
[cited by applicant]
U.S. Appl. No. 17/345,928 Notice of Allowance dated Dec. 22, 2021.
[cited by applicant]
Yuting et al., α1-antitrypsin Platinum deficiency and treatment. Advances in Microbiology and Immunology 43(3): 72-75 (2015).
[cited by applicant]